Clinical Trial Update: Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial compares adding golidocitinib to a P-GemOx regimen plus a PD-1 inhibitor against P-GemOx plus a PD-1 inhibitor as first-line therapy for advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma
• Extranodal Nk T-cell Lymphoma Nasal Type
• Extranodal Nk T-cell Lymphoma Non-nasal Type

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Golidocitinib (golidocitinib)
• OXALIPLATIN (Oxaliplatin)
• PD-1 inhibitor

Snippet

Sponsor: WEI XU | Conditions: Extranodal NK/T-cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING